Skip to main content
ARGNF logo

argenx SE (ARGNF) Stock Price & Analysis

argenx SE (ARGNF) — price $965.00 (0.00%), as of the Nov 18, 2026 trading session; market cap $60.7B.

Educational signal · not a buy or sell recommendation · How to read this

$965.00 $0.00 (0.00%) Market Cap $60.7B

argenx SE · ARGNF · Healthcare · Biotechnology

argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions.

Price as of Nov 18, 2026

Key Statistics

No MoonshotScore yet: we have not published a score for this company.

Thousands of the 20,000+ US stocks here carry a MoonshotScore.

Scored companies in the same industry:

  • RPRX · Royalty Pharma plc · 73 /100
  • REGN · Regeneron Pharmaceuticals, Inc. · 95 /100
  • GMAB · Genmab A/S · 72 /100

See all scored stocks →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$965.00
Change on the day0.00%
52-week range$712.02–$1020.00
Market capitalisation$60.7B
Price / earnings (trailing)44.14
Shares traded on the day49
Beta (volatility vs the S&P 500)-0.02

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 18, 2026: low $712, high $1,020, latest $965. $1,020 $712 high $1,020 Oct 17, 2025 Nov 18, 2026 · $965 $834Oct 17, 2025$786Oct 31, 2025$870Nov 14, 2025$870Nov 28, 2025$870Dec 12, 2025$870Dec 26, 2025$817Jan 9, 2026$817Jan 23, 2026$842Feb 6, 2026$815Feb 20, 2026$815Mar 6, 2026$815Mar 20, 2026$712Apr 2, 2026$712Apr 17, 2026$725May 1, 2026$803May 15, 2026$835May 29, 2026$900Jun 12, 2026$900Jun 26, 2026$935Jul 10, 2026$865Jul 24, 2026$865Aug 7, 2026$995Aug 21, 2026$1,014Sep 4, 2026$1,010Sep 18, 2026$936Oct 2, 2026$790Oct 16, 2026$900Oct 30, 2026$965Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for argenx SE (ARGNF): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Legends Council

4 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Englander-style lens (simulated) Izzy Englander Neutral read
Klarman-style lens (simulated) Seth Klarman Unfavorable read
Moon AI lens (model) Favorable read

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Strong
Margin of Safety Overvalued
Profit Margin Strong
Revenue Growth Strong
Debt/Equity Strong
ROE Moderate
Gross Margin Strong

Read on: Sep 10, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Sep 10, 2026, the Munger lens read the price at that time as overvalued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is argenx SE (ARGNF), and what does it report?

Short answer · as of

argenx SE is a biotechnology enterprise dedicated to developing a diverse array of therapeutic agents for autoimmune conditions. argenx SE (ARGNF) is classified as Healthcare / Biotechnology. SEC filing business address: Industriepark Zwijnaarde 7, Building C B-9052, Zwijnaarde. It employs 1,863 people and is led by Karen Massey. In Q4 FY2026 it reported revenue of $1.72B and net income of $506M. The market values it at $60.7B.

2 · Latest results

What do the latest results show for argenx SE (ARGNF)?

Short answer · as of

The most recent reported quarter, Q4 FY2026, carried revenue of $1.72B. Against analyst estimates the company has EPS beat 5 of the last 8 reports.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Q4 FY2026$1.72B$506M$7.80 (diluted)
Q2 FY2026$2.75B$820M$12.74 (diluted)
Q4 FY2025$2.43B$883M$13.34 (diluted)
Q2 FY2025$948M$245M$6.32 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for argenx SE (ARGNF)?

Short answer · as of

Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway. The distress and quality screens read Altman Z 22.20 · Piotroski F 4. Trailing ratios: ROE 16.9% · ROA 13.2% · current ratio 5.12 · earnings yield 2.2% · free-cash-flow yield 1.8%.

The records behind this page

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held ARGNF in their latest 13F filing, and what they did against the filing before it.

None of the 16 tracked investors reported ARGNF in their latest 13F filing.

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about argenx SE (ARGNF)?

Read these with our analysis →

ARGNF Healthcare Stock FAQ

These answers are editorial: 1 of these 8 answers is drawn from the ARGNF research dossier (written Mar 18, 2026 by gemini-2.0-flash); the other 7 are question templates that restate figures shown above. Figures in this section are not part of the source register.

Is ARGNF a good stock to buy?

Stock Expert AI does not rate ARGNF buy, sell or hold. argenx SE has no MoonshotScore yet; read the financial checkup, analyst consensus and risks directly. Whether it fits is your call: check what it sells, whether it earns and what the price assumes. This is educational content, not investment advice.

What is the ARGNF stock price today?

The last price recorded for argenx SE (ARGNF), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What are the main risks for ARGNF?

The main risks for argenx SE include clinical trial failures for its product candidates, particularly efgartigimod, which is in late-stage development.

What are the key factors to evaluate for ARGNF?

Evaluate ARGNF on fundamentals, analyst consensus, and risk factors. To weigh it, start with the trailing P/E under Price & valuation on this page. Lead product candidate, efgartigimod, in Phase III clinical trials for multiple autoimmune indications, representing near-term revenue potential. Not financial advice.

How frequently does ARGNF data refresh on this page?

ARGNF's price is the last quote we recorded, from the Nov 18, 2026 trading session. Pages are served from a cache, so the copy you are reading can lag that quote. The quote is a provider snapshot, not an exchange feed. Fundamentals follow quarterly filings. V2 is recalculated from the most recent completed US trading session; the score's own date shows its last successful run.

What has driven ARGNF's recent stock price performance?

argenx SE (ARGNF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative technology platform for antibody development. See the News tab for the latest drivers. Past performance does not predict future results.

Should investors consider ARGNF overvalued or undervalued right now?

The trailing P/E of argenx SE (ARGNF) is listed under Price & valuation on this page. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.

How do I research ARGNF before investing?

Before investing in argenx SE (ARGNF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).

Machine-generated analysis by Stock Expert AI — model gemini-2.0-flash, generated Mar 18, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 20 from Financial Modeling Prep (FMP) and 3 with no recorded source. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.